Tirzepatide Coupon: Mounjaro & Zepbound Savings Guide 2026
Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss) costs $1,400-$1,600 per month at full price, but Eli Lilly\'s savings card can reduce your out-of-pocket cost to $0-$250/month. Tirzepatide is a dual GIP/GLP-1 agonist—more effective than semaglutide for weight loss—and offers roughly comparable pricing with coupons. This guide covers how the tirzepatide coupon works, insurance strategies, patient assistance programs, and compounded tirzepatide alternatives that cost 75-85% less than brand-name.
Understanding Tirzepatide: Dual GIP/GLP-1 Agonist
Tirzepatide is a newer class of weight-loss and diabetes medication compared to semaglutide. It works through two mechanisms instead of one, making it more potent.
What Makes Tirzepatide Different:
- Semaglutide: GLP-1 agonist only (targets one hormone pathway)
- Tirzepatide: Dual GIP/GLP-1 agonist (targets two hormone pathways simultaneously)
- Implication: Tirzepatide is more potent; better weight loss + glucose control
Clinical Efficacy Comparison:
- Semaglutide (Ozempic/Wegovy): 10-15 lbs weight loss, HbA1c reduction ~1-2%
- Tirzepatide (Mounjaro/Zepbound): 15-20 lbs weight loss, HbA1c reduction ~1.5-2.5%
- Advantage: Tirzepatide achieves ~25% more weight loss than semaglutide
Available Dosages (Tirzepatide):
- 2.5 mg (starting dose)
- 5 mg
- 7.5 mg (standard dose)
- 10 mg (maximum dose)
- 15 mg (highest available; some patients titrate up)
Dosing Schedule:
- Frequency: Once weekly injection (same as semaglutide)
- Form: Prefilled pens (Mounjaro/Zepbound)
- Route: Subcutaneous injection (abdomen, thigh, or arm)
Tirzepatide Brands: Mounjaro vs Zepbound
Eli Lilly produces two brand names for tirzepatide, marketed for different indications but containing identical medication.
Brand Comparison:
| Brand | FDA Indication | Primary Use | List Price |
|---|---|---|---|
| Mounjaro | Type 2 diabetes | Glucose control + weight loss | $1,400-$1,600/mo |
| Zepbound | Weight loss (obesity) | Weight loss + metabolic health | $1,400-$1,600/mo |
Key Insight:
Mounjaro and Zepbound are therapeutically identical—same tirzepatide molecule, same weekly injection, same dosages. The difference is purely marketing and FDA indication. Insurance coverage may differ between the two; some plans cover Mounjaro (diabetes) better than Zepbound (weight loss). Both qualify for Eli Lilly\'s unified savings card.
Which Should I Choose?
- Choose Mounjaro if: You have type 2 diabetes and/or your insurance covers diabetes indication better
- Choose Zepbound if: Your primary goal is weight loss and your insurance covers weight-loss indication better
- Cost-wise: Identical with manufacturer coupons ($250/month uninsured, $50-$100/month insured)
Eli Lilly Tirzepatide Savings Card
Eli Lilly offers a unified savings card that works for both Mounjaro (diabetes) and Zepbound (weight loss). You don\'t need separate coupons for each brand.
How Much You\'ll Save:
- Insured patients: Often $0-$100 copay (additional reduction on top of insurance)
- Uninsured patients: Capped at $250/month
- Low-income uninsured: May qualify for $0-$50/month with patient assistance
Full Price Without Coupon:
- Mounjaro: $1,400-$1,600/month
- Zepbound: $1,400-$1,600/month
How to Get the Card:
- Visit lilly.com and search "Mounjaro savings card" or "Zepbound coupon"
- Fill out brief form (takes 2-3 minutes)
- Receive digital code immediately or physical card by mail
- Present at pharmacy when filling prescription
- Discount applied automatically
Alternative Access Methods:
- Call Eli Lilly patient support: 1-800-545-5979
- Ask your doctor\'s office for card
- Ask your pharmacist (major chains distribute)
Medicare & Medicaid Limitation:
Federal law prohibits manufacturer coupons for Medicare/Medicaid patients. If you\'re on government insurance, you must use Eli Lilly\'s patient assistance program instead. Contact patient support to check eligibility.
Tirzepatide With Insurance + Savings Card
If you have commercial insurance, combining coverage with Eli Lilly\'s savings card gives you the best pricing for brand tirzepatide.
Example Scenarios:
Scenario 1: Good Insurance Coverage
- Insurance copay: $50/month
- Eli Lilly savings card: Additional $15-$25 reduction
- Your final out-of-pocket: $25-$35/month
Scenario 2: High Deductible (Not Met)
- Insurance doesn\'t cover yet (in deductible): Full price $1,500
- Eli Lilly savings card: Reduces to $250
- Your final out-of-pocket: $250/month until deductible met
Scenario 3: Non-Preferred Drug (High Copay)
- Insurance copay for non-preferred: $300/month
- Eli Lilly savings card: May cap at $250
- Your final out-of-pocket: $250/month
How to Combine Benefits:
- Call insurance to verify tirzepatide (Mounjaro or Zepbound) coverage
- Ask copay amount and if prior authorization required
- Get prescription from doctor
- Enroll in Eli Lilly savings card (lilly.com)
- Present both insurance card + savings card at pharmacy
- Pharmacy applies both; you pay the lower amount
Tirzepatide Without Insurance
Uninsured patients can access tirzepatide through Eli Lilly\'s savings card at a flat $250/month cap, significantly reduced from the $1,400-$1,600 full price.
Uninsured Cost Structure:
- Mounjaro (any dose) with card: $250/month
- Zepbound (any dose) with card: $250/month
- Without card (cash): $1,400-$1,600/month
- Savings: 83% discount with card
Access Path:
- Get prescription from doctor or telehealth provider
- Enroll in Eli Lilly savings card (free, 2 minutes)
- Fill at any US pharmacy with card code
- Pay $250/month capped price
Comparison to Semaglutide:
- Tirzepatide with card: $250/month uninsured
- Semaglutide with card: $250/month uninsured
- Cost difference: Identical when using manufacturer coupons
- Efficacy difference: Tirzepatide 25% more effective for weight loss
Uninsured patients pay same price for both drugs but get better results with tirzepatide. If cost is identical, tirzepatide is the superior choice unless semaglutide is specifically preferred by your doctor.
Eli Lilly Patient Assistance Program
For uninsured, low-income patients, Eli Lilly\'s patient assistance program provides free or heavily discounted tirzepatide.
Eligibility:
- Uninsured or underinsured
- Household income below 300-400% federal poverty level (roughly $60,000-$130,000 depending on family size)
- Valid prescription for tirzepatide (Mounjaro or Zepbound)
- US resident
How to Apply:
- Call Eli Lilly patient assistance: 1-800-545-5979
- Ask for "patient assistance program" or "co-pay assistance"
- Provide doctor\'s name, household income, insurance status
- Receive application (mail or online)
- Submit income documentation (recent pay stubs or tax return)
- Program reviews (typically 1-2 weeks)
- Once approved: Receive tirzepatide free or at low copay ($0-$50/month)
Documentation Needed:
- Valid prescription for tirzepatide
- Proof of income (2 recent pay stubs or tax return)
- Proof of residency (utility bill, lease agreement)
- Insurance status information
Benefits:
- Free or $0-$25/month tirzepatide
- Ongoing refills (usually auto-renew annually)
- Shipped to you or available at pharmacy
- No insurance required
Compounded Tirzepatide: Emerging Budget Alternative
Compounded tirzepatide is becoming increasingly available as licensed pharmacies develop preparations. This offers 75-85% savings compared to brand.
Cost Comparison:
- Brand tirzepatide (full price): $1,400-$1,600/month
- Brand tirzepatide (with savings card): $250/month
- Compounded tirzepatide: $200-$500/month
- Savings with compounded: 70-85% off brand price
Availability & Status:
- Compounded tirzepatide is newer than compounded semaglutide
- Less widely available but growing rapidly (2025-2026)
- Regulatory status appears stable; FDA has not restricted like some compounded options
- Quality highly variable; must vet compounding pharmacy carefully
Pros of Compounded Tirzepatide:
- Significant cost savings (70-85% off brand)
- Same active ingredient as brand Mounjaro/Zepbound
- Legal when from licensed compounding pharmacy
- More effective than semaglutide at same cost (if you were choosing between them)
Cons of Compounded Tirzepatide:
- Quality varies significantly between pharmacies
- Less established regulatory history than semaglutide compounding
- Insurance doesn\'t cover (cash pay only)
- Less extensive third-party testing data available
- Vials instead of pens; requires reconstitution
How to Vet a Compounding Pharmacy for Tirzepatide:
- Verify state pharmacy board licensing
- Check for PCAB (Pharmacy Compounding Accreditation Board) accreditation
- Verify USP <797> compliance (sterility standards)
- Request third-party testing results for potency and purity
- Ask about raw material sourcing (should be pharmaceutical-grade)
- Read patient reviews on Reddit and Google
- Get quotes from multiple pharmacies; compare quality + pricing
- Ask about their tirzepatide compounding experience (newer area)
Red Flags to Avoid:
- No PCAB accreditation or state licensing verification
- Cannot provide third-party testing documentation
- Vague about raw material sourcing
- Suspiciously cheap pricing (below $150-$200/month)
- Heavily negative reviews from patients
- Marketed as "research" rather than licensed pharmacy
Tirzepatide vs Semaglutide: Head-to-Head Comparison
| Factor | Tirzepatide (Mounjaro/Zepbound) | Semaglutide (Ozempic/Wegovy) |
|---|---|---|
| Mechanism | Dual GIP/GLP-1 agonist | GLP-1 agonist only |
| Weight loss (average) | 15-20 lbs at max dose | 10-15 lbs at max dose |
| Diabetes HbA1c reduction | 1.5-2.5% reduction | 1-2% reduction |
| Full price (monthly) | $1,400-$1,600 | $1,200-$1,450 |
| With manufacturer card (uninsured) | $250 | $250 |
| With insurance (typical) | $50-$100 | $50-$100 |
| Compounded option available | Yes (emerging; $200-$500/mo) | Yes (established; $150-$400/mo) |
| Dosing frequency | Once weekly | Once weekly |
| Injectable/oral options | Injectable only (pens) | Injectable (pens) or oral (Rybelsus) |
| Side effect profile | Similar to semaglutide | Similar to tirzepatide |
| FDA approval timeline | 2022-2023 | 2017-2021 |
| Long-term data | Shorter duration available | Extensive long-term safety data |
| Biosimilar timeline | 2027-2029 expected | 2026-2028 expected |
Which Should You Choose?
- Choose Tirzepatide if: (1) You want maximum weight loss, (2) You have type 2 diabetes needing strong control, (3) Cost is identical so get more effective option, (4) Your insurance covers both equally
- Choose Semaglutide if: (1) Your insurance prefers semaglutide (lower copay), (2) You want more established long-term data (available longer), (3) You prefer future option of oral form (Rybelsus) and compounded versions (established longer), (4) Doctor recommends based on your specific situation
- Bottom line: Both cost the same with coupons; tirzepatide is more effective. If insurance allows, tirzepatide is arguably the better choice.
Tirzepatide Insurance Coverage: Mounjaro vs Zepbound
Insurance coverage differs between Mounjaro (diabetes) and Zepbound (weight loss), similar to semaglutide differences. Understanding this helps optimize your coverage.
Coverage Differences:
- Mounjaro: Covered by most commercial plans as diabetes medication (after prior auth)
- Zepbound: Increasingly covered but some plans still deny weight loss as "cosmetic"
Strategy if Coverage Differs:
- Call insurance to compare copays for Mounjaro vs Zepbound
- If Mounjaro has lower copay, ask doctor to prescribe Mounjaro
- Active ingredient is identical; therapeutic results equivalent
- Only difference is FDA indication; clinical efficacy same
Strategy if Both Well-Covered:
- Choose based on your primary need (diabetes vs weight loss)
- Or choose based on doctor\'s preference
- Cost and efficacy identical; no financial advantage either way
Cost Comparison: Tirzepatide vs All GLP-1/GIP Alternatives
| Medication | Type | Full Price | With Coupon | With Insurance | Compounded Option |
|---|---|---|---|---|---|
| Tirzepatide (Mounjaro/Zepbound) | Dual GIP/GLP-1 | $1,400-$1,600 | $250 | $50-$100 | $200-$500 |
| Semaglutide (Ozempic/Wegovy) | GLP-1 only | $1,200-$1,450 | $250 | $50-$100 | $150-$400 |
| Liraglutide (Saxenda/Victoza) | GLP-1 only | $900-$1,200 | Variable | $50-$150 | $100-$300 |
| GLP-1 patient assistance (income-qualified) | Various | N/A | $0-$50 | N/A | N/A |
Tirzepatide Prior Authorization: What to Expect
Many insurance plans require prior authorization (pre-approval) before covering tirzepatide. Understanding this process helps manage timeline expectations.
What Triggers Prior Auth:
- New prescription for tirzepatide (any brand)
- First-time use in patient (some plans)
- Off-label use (e.g., non-diabetic patient on Mounjaro for weight loss)
- Quantity/frequency different than expected
Timeline:
- Typical: 2-5 business days
- Expedited: Can be 24 hours if marked STAT/urgent
- Denial: Possible but uncommon; doctor can appeal
Speed It Up:
- At doctor visit, ask them to submit prior auth immediately (before you leave)
- Doctor faxes your medical record proving diabetes or obesity diagnosis
- Insurance reviews (typically 2-5 days)
- You get approval notification via email/phone
While Waiting:
- Pay out-of-pocket with Eli Lilly savings card ($250/month)
- Once approved, submit receipt for reimbursement (some plans allow; ask)
- This ensures you start treatment without waiting
Step-by-Step: Getting Cheapest Tirzepatide
If You Have Insurance:
- Call insurance to verify tirzepatide (Mounjaro or Zepbound) coverage
- Ask copay and whether prior authorization required
- Get prescription from doctor (they can submit prior auth)
- Enroll in Eli Lilly savings card (lilly.com)
- Fill at pharmacy with both insurance + card
- Pay the lower amount (usually $50-$100/month)
If You\'re Uninsured & Can Afford $250/month:
- Get prescription from doctor or telehealth
- Enroll in Eli Lilly savings card (free, 2 minutes)
- Fill at any pharmacy with card code
- Pay $250/month capped price
If You\'re Uninsured & Low-Income:
- Apply for Eli Lilly patient assistance (1-800-545-5979)
- If income-qualified: Receive free or $0-$25/month tirzepatide
- If not approved: Use savings card ($250/month) OR
- Switch to compounded tirzepatide ($200-$500/month) if available in your area
If Budget Is Critical (<$200/month):
- Research compounding pharmacies specializing in tirzepatide
- Verify PCAB accreditation, state licensing, third-party testing
- Get quotes from 3-5 pharmacies ($200-$500/month typical)
- Choose based on quality (not just lowest price)
- Use GoodRx to compare compounding pharmacy pricing if needed
Tirzepatide Side Effects & Management
Understanding side effects helps you anticipate issues and stick with treatment.
Most Common Side Effects:
- Nausea (40-50%): Most common; usually improves within 2-3 weeks
- Vomiting (15-20%): Usually mild; improves quickly
- Diarrhea (20-30%): Common GLP-1/GIP class effect
- Constipation (15%): Some patients alternate diarrhea/constipation
- Headache (10%): Mild, usually temporary
- Dehydration risk: Higher with nausea/vomiting
Management:
- Start with lowest dose (2.5 mg) and titrate slowly
- Stay well-hydrated (drink 8-10 glasses water daily)
- Small, frequent meals rather than large meals
- Most side effects resolve within 2-3 weeks
- Can take anti-nausea medication if needed (discuss with doctor)
Future Tirzepatide Pricing: When Will It Get Cheaper?
Understanding patent timelines helps you decide when to wait for cheaper options vs starting now.
Tirzepatide Patent Timeline:
- Eli Lilly tirzepatide patents: Extend to roughly 2031-2033
- Key patent expirations: Spread across 2031-2034 depending on specific patents
- Patent litigation: Will likely extend exclusivity beyond nominal dates
Biosimilar Tirzepatide Timeline:
- Expected approval: 2027-2029 (later than semaglutide biosimilars at 2026-2028)
- Manufacturers developing: Pfizer, Amgen, others pursuing biosimilar tirzepatide
- Expected price reduction: 15-35% off brand price when approved
- Estimated cost: ~$1,000-$1,300/month (still more than compounded options available now)
Recommendation:
Don\'t wait 5+ years for biosimilar approval. Options available now: (1) Brand tirzepatide with Eli Lilly card ($250/month uninsured), (2) Compounded tirzepatide ($200-$500/month; emerging but increasingly available), (3) Patient assistance if income-qualified (free). All save significantly vs full price. Start treatment now rather than waiting for future price reductions.
Frequently Asked Questions
Eli Lilly's tirzepatide savings card can reduce out-of-pocket cost to $0-$250/month depending on insurance status, similar to semaglutide programs. Insured patients typically pay $0-$100 copay with the card. Uninsured patients cap out at $250/month (from $1,500+ full price). Low-income patients may qualify for free medication through patient assistance programs.
Mounjaro and Zepbound are both tirzepatide but marketed differently. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for weight loss in obesity. Both contain identical tirzepatide (dual GIP/GLP-1 agonist). They use the same manufacturer savings card from Eli Lilly. Cost and efficacy are essentially identical; only the FDA indication differs.
Yes, tirzepatide (dual GIP/GLP-1 agonist) is generally more effective than semaglutide (GLP-1 only) for weight loss. Clinical trials show tirzepatide produces 10-20 lbs more weight loss than semaglutide over 3-6 months at equivalent doses. For diabetes control, tirzepatide achieves slightly better HbA1c reduction. However, side effects are similar. Both are powerful medications; tirzepatide offers marginal additional benefit at similar cost.
Visit lilly.com and search "Mounjaro savings card" or "Zepbound savings card." Complete brief form (2-3 minutes). Get digital code immediately or physical card by mail. Present at any pharmacy when filling tirzepatide prescription. Pharmacy applies discount automatically. Works with insurance (copay + card) or without insurance (flat $250/month cap).
Yes, Eli Lilly's tirzepatide savings card caps uninsured patients at $250/month (down from $1,500+ full price). You can also apply for Eli Lilly patient assistance program if low-income, potentially getting free medication. Both routes are available to uninsured patients. Cost-wise, tirzepatide and semaglutide are equivalent with manufacturer coupons.
Yes, compounded tirzepatide is becoming increasingly available from licensed compounding pharmacies. Like compounded semaglutide, it costs 75-85% less than brand ($200-$500/month typical). Quality varies by pharmacy; vet for PCAB accreditation, third-party testing, and licensing before ordering. Compounded tirzepatide offers similar efficacy to brand at substantial savings.
Federal law prohibits manufacturer coupons for Medicare/Medicaid patients. You cannot use Eli Lilly's tirzepatide savings card. However, Eli Lilly's patient assistance program may help (income-based). Contact Eli Lilly patient support (1-800-545-5979) to check eligibility. Some state Medicaid programs cover tirzepatide; check your specific plan. Consider compounded tirzepatide as alternative.
Choose tirzepatide (Mounjaro/Zepbound) if: (1) You want maximum weight loss (10-20 lbs more than semaglutide), (2) You have type 2 diabetes (better HbA1c reduction), (3) Cost is similar so might as well get more effective option. Choose semaglutide if: (1) Your insurance prefers semaglutide or has better coverage, (2) You're concerned about side effects (profiles similar), (3) You want future option of compounded semaglutide (established longer than compounded tirzepatide). Efficacy-wise, tirzepatide wins slightly; choice may depend on insurance coverage.
Tirzepatide (dual GIP/GLP-1) is the most effective weight-loss medication available (10-20 lbs typical at max dose). Semaglutide (GLP-1 only) is nearly as effective (10-15 lbs typical). Other options: liraglutide (less effective, ~6-8 lbs), older drugs like phentermine (less effective, ~5-7 lbs), or topiramate/phentermine combination (6-10 lbs). Cost-wise, tirzepatide and semaglutide are similar; efficacy-wise, tirzepatide edges out semaglutide. Both beat traditional weight-loss medications substantially.
Tirzepatide is a biologic; true generics will never exist. Eli Lilly patents extend to roughly 2031-2033. Biosimilar tirzepatide may become available 2027-2029 (later than semaglutide biosimilars). Expected price reduction: 15-35% off brand. Biosimilar cost estimated ~$1,000-$1,300/month (still more than compounded options available now). Don't wait years for biosimilars; use coupons ($250/month) or compounded ($200-$500/month) today.
Compounded tirzepatide from reputable licensed pharmacies (PCAB-accredited, third-party tested) is safe and effective. It contains identical tirzepatide molecule. Quality control varies by pharmacy, so vet carefully. Lower oversight than brand-name, but when sourced properly, offers same therapeutic results at 75-85% lower cost. Regulatory status is less certain than semaglutide (newer compounding area), but appears stable in 2026.
Related Resources & Guides
Key Takeaway: Tirzepatide (Mounjaro/Zepbound) costs $250/month with Eli Lilly\'s savings card for uninsured patients—identical to semaglutide pricing. However, tirzepatide is 25% more effective for weight loss and has stronger diabetes control. For insured patients, both typically cost $50-$100/month copay. For maximum savings, compounded tirzepatide ($200-$500/month) is emerging as an option. If cost is equal, tirzepatide is the superior choice for efficacy. Always vet compounding pharmacies carefully before ordering.
Medical Disclaimer: This guide is informational only. Tirzepatide must only be used under supervision of a licensed healthcare provider. Always ensure you\'re buying from legitimate sources. Verify pharmacy licensing with your state pharmacy board. Consult your doctor about whether tirzepatide or semaglutide is best for your specific medical situation and goals.